France and the Global Fund to Fight AIDS, Tuberculosis and Malaria

Over 20 years of partnership between France and the Global Fund have played a great role in the fight against HIV, tuberculosis (TB) and malaria and in building a healthier, safer and more equitable world.

Our partnership

France is the largest European donor to the Global Fund and the second largest public donor overall, with a total contribution of €6.51 billion to date. When France hosted the Global Fund’s Sixth Replenishment Conference in 2019, the Global Fund mobilized more than US$14 billion, of which €1.296 billion from France, a 20% increase compared to its Fifth Replenishment pledge. At the Seventh Replenishment in 2022, France pledged €1.596 billion – a 23% increase from its previous contribution.

Health investments through the Global Fund have saved more than 59 million lives since 2002.

Efforts by governments, communities and global health partners have resulted in extraordinary progress in the fight against the three diseases. In countries where the Global Fund invests, in 2022:

- 24.5 million people were on antiretroviral therapy for HIV.
- 6.7 million people were treated for TB.
- 220 million mosquito nets were distributed.

L’Initiative

The Global Fund collaborates closely with L’Initiative to accelerate the fight against the three diseases and build strong health systems. Implemented by Expertise France, L’Initiative is funded by the set-aside of France’s pledge to the Global Fund and supports interventions in 40 countries. L’Initiative strengthens in-country pandemic preparedness and response plans, supports countries to develop funding requests for Global Fund grants and enhances the impact and efficiency of these grants. L’Initiative funds a gender-focused project to support safer births in Madagascar and co-funds a Unitaid project to prevent cervical cancer among women living with HIV. It finances the field epidemiologist master’s degree at the University of Lomé (Togo) and contributes to strengthening community-based organizations so that they can provide high-quality health services that are integrated into the national health system. It represents 20% of France’s commitment to the Global Fund, with €319 million forecast for Grant Cycle 7 (2023-2025).

France’s pledges and contributions to the Global Fund (in € billion)

Priority areas of our partnership
The Global Fund's strategy and focused investments are strongly aligned with France's Strategy for Global Health.

Health and community systems strengthening
The Global Fund invests over US$2 billion every year in more than 110 countries to strengthen health and community systems. Human resources for health (HRH) is a priority area that underpins our investments to strengthen health systems and pandemic preparedness. Over the 2024-2026 period, we are investing over US$900 million in community health workers, a 55% increase on the previous three-year period. Aligned with national plans, our programs finance the policies that build a strong infrastructure for community health workers. In Togo, the Global Fund supports critical activities led by community health workers, including TB contact-tracing and sample collection from people with undiagnosed TB in the community. This has had a major impact against the disease: In 2022, Togo achieved 100% treatment coverage for TB and an 87% treatment success rate. This outreach work is also relevant in response to other health threats.

Gender equality and sexual and reproductive health and rights
Around 4,000 adolescent girls and young women become infected with HIV every week. But targeted investments in HIV treatment and prevention interventions have led to a 67% reduction in the HIV incidence rate among adolescent girls and young women in 13 focus countries in sub-Saharan Africa since 2010, indicating the effectiveness of focused interventions. In 2022, 2.5 million adolescent girls and young women were reached with HIV prevention programs in the same 13 countries.

Regional manufacturing of health products
As part of our Next Generation Market Shaping Approach, the Global Fund is promoting capacity building for regional manufacturing across the regions where we invest, with an initial focus on Africa. In August 2023, the Global Fund, in partnership with PEPFAR and Unitaid, launched a pilot review process for African manufacturers of HIV rapid diagnostic tests (RDTs) to accelerate the production of RDTs on the continent. To secure a sufficient and equitable supply of health products, in 2022 the Global Fund procured 17% of artemether-lumefantrine (an antimalarial medicine), 19% of insecticide-treated mosquito nets and 98% of the antibiotic co-trimoxazole from African manufacturing sites.

Country ownership and inclusive governance
Countries where the Global Fund invests take the lead in determining where and how to best fight the three diseases. Country Coordinating Mechanisms – the national committees that include representatives of all sectors involved in the response to the diseases – submit funding applications to the Global Fund and oversee grants on behalf of their countries. They are a key element of the Global Fund partnership.

Strong coordination with international partners
In the spirit of multilateralism, the Global Fund fosters meaningful and effective partnerships with the private sector and the public sector – including with the World Health Organization; Unitaid; Gavi, the Vaccine Alliance (Gavi); the World Bank; and regional institutions like the Africa Centres for Disease Control and Prevention. We work together with our partners to build strong and resilient systems for health and achieve maximum impact against the three diseases.

Cameroon: One country's fight to keep mothers and children safe from malaria
To stay ahead of malaria, the Global Fund works closely with partners to develop, invest in and deploy new tools and innovations. Cameroon is at the forefront of this evolution.

Cameroon’s government, with support from the Global Fund, Gavi, the U.S. President’s Malaria Initiative and others, is simultaneously rolling out the newest mosquito nets, preventive treatment for young children and pregnant women, the new malaria vaccine, as well as community-based testing and treatment services. In 2024, Cameroon became the first country in the world to incorporate the new RTS,S malaria vaccine into its routine national child immunization program. The Global Fund worked together with Unitaid and Gavi to fund the initial pilot programs for the vaccine. And Global Fund investments in local health systems have been vital in supporting the malaria vaccine’s rollout in Cameroon.

Global Fund investments also support Cameroon’s mass mosquito net distribution campaigns across the country. These tools and interventions – combined with political and financial commitment and strong partnerships among government, health agencies, civil society and communities – can make a real difference.

About the Global Fund
The Global Fund is a worldwide partnership to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest more than US$5 billion a year to fight the deadliest infectious diseases, challenge the injustice that fuels them, and strengthen health systems and pandemic preparedness in more than 100 of the hardest hit countries. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund partnership has saved 59 million lives.

June 2024 | www.theglobalfund.org